Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-Gemox regimen in relapsed or refractory AITL
ChiCTR2300075967Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of duvelisib and tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete response rate and Progression-free survival. Started Oct 2023; status: recruiting.
02
Drugs
duvelisibtucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on ChiCTR2300075967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075967.